These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33882179)

  • 21. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial.
    Busani S; Tosi M; Mighali P; Vandelli P; D'Amico R; Marietta M; Forfori F; Donati A; Cinnella G; De Monte A; Pasero D; Bellani G; Tascini C; Foti G; Ranieri M; Girardis M
    Trials; 2020 Aug; 21(1):724. PubMed ID: 32807241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.
    Kyriakopoulos C; Ntritsos G; Gogali A; Milionis H; Evangelou E; Kostikas K
    Respirology; 2021 Nov; 26(11):1027-1040. PubMed ID: 34605114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
    Veiga VC; Prats JAGG; Farias DLC; Rosa RG; Dourado LK; Zampieri FG; Machado FR; Lopes RD; Berwanger O; Azevedo LCP; Avezum Á; Lisboa TC; Rojas SSO; Coelho JC; Leite RT; Carvalho JC; Andrade LEC; Sandes AF; Pintão MCT; Castro CG; Santos SV; de Almeida TML; Costa AN; Gebara OCE; de Freitas FGR; Pacheco ES; Machado DJB; Martin J; Conceição FG; Siqueira SRR; Damiani LP; Ishihara LM; Schneider D; de Souza D; Cavalcanti AB; Scheinberg P;
    BMJ; 2021 Jan; 372():n84. PubMed ID: 33472855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Tocilizumab in Mortality among Patients with Severe and Critical Covid-19: Experience in a Third-Level Medical Center.
    Martínez-Guerra BA; de-León-Cividanes NA; Tamez-Torres KM; Román-Montes CM; Rajme-López S; Ortiz-Brizuela E; Aguilar-Salinas CA; Sierra-Madero J; Sifuentes-Osornio J; Ponce-de-León A; González-Lara MF
    Rev Invest Clin; 2022 Jan; 74(1):40-50. PubMed ID: 34618802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study.
    Huang E; Isonaka S; Yang H; Salce E; Rosales E; Jordan SC
    Int J Infect Dis; 2021 Apr; 105():245-251. PubMed ID: 33609773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials.
    Snow TAC; Saleem N; Ambler G; Nastouli E; Singer M; Arulkumaran N
    Intensive Care Med; 2021 Jun; 47(6):641-652. PubMed ID: 34019122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2.
    Petrak RM; Skorodin NC; Van Hise NW; Fliegelman RM; Pinsky J; Didwania V; Anderson M; Diaz M; Shah K; Chundi VV; Hines DW; Harting BP; Sidwha K; Yu B; Brune P; Owaisi A; Beezhold D; Kent J; Vais D; Han A; Gowda N; Sahgal N; Silverman J; Stake J; Nepomuceno J; Heddurshetti R
    Clin Transl Sci; 2021 Nov; 14(6):2146-2151. PubMed ID: 32918792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2021 May; 397(10285):1637-1645. PubMed ID: 33933206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients.
    West TA; Malik S; Nalpantidis A; Tran T; Cannon C; Bhonagiri D; Chan K; Cheong E; Wan Sai Cheong J; Cheung W; Choudhury F; Ernest D; Farah CS; Fernando S; Kanapathipillai R; Kol M; Murfin B; Naqvi H; Shah A; Wagh A; Ojaimi S; Frankum B; Riminton S; Keat K
    Int J Rheum Dis; 2020 Aug; 23(8):1030-1039. PubMed ID: 32881350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial.
    Dushianthan A; Clark H; Madsen J; Mogg R; Matthews L; Berry L; de la Serna JB; Batchelor J; Brealey D; Hussell T; Porter J; Djukanovic R; Feelisch M; Postle A; Grocott MPW
    Trials; 2020 Dec; 21(1):1014. PubMed ID: 33302976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).
    Juul S; Nielsen EE; Feinberg J; Siddiqui F; Jørgensen CK; Barot E; Holgersson J; Nielsen N; Bentzer P; Veroniki AA; Thabane L; Bu F; Klingenberg S; Gluud C; Jakobsen JC
    PLoS One; 2021; 16(3):e0248132. PubMed ID: 33705495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
    Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
    Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tocilizumab in the Management of COVID-19: A Preliminary Report.
    Li M; Yoo EJ; Baram M; McArthur M; Skeehan C; Awsare B; George G; Summer R; Zurlo J; Jallo J; Roman J
    Am J Med Sci; 2021 Feb; 361(2):208-215. PubMed ID: 33358502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
    Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C;
    J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.
    Rosas IO; Bräu N; Waters M; Go RC; Hunter BD; Bhagani S; Skiest D; Aziz MS; Cooper N; Douglas IS; Savic S; Youngstein T; Del Sorbo L; Cubillo Gracian A; De La Zerda DJ; Ustianowski A; Bao M; Dimonaco S; Graham E; Matharu B; Spotswood H; Tsai L; Malhotra A
    N Engl J Med; 2021 Apr; 384(16):1503-1516. PubMed ID: 33631066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
    Marietta M; Vandelli P; Mighali P; Vicini R; Coluccio V; D'Amico R;
    Trials; 2020 Jun; 21(1):574. PubMed ID: 32586394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.